Sign In
Buy CYDY
$0.276
-0.0143 (-4.93%)
At Close: Jun 03, 2026
CytoDyn to Present at the LD Micro Invitational XVI
08:30am, Friday, 15'th May 2026
CFO Robert E. Hoffman to deliver company presentation on May 18 at 10 a.m.
CytoDyn Inc. (CYDY) Discusses Corporate and Clinical Update With Focus on Leronlimab Development and Recent Financing Transcript
05:41am, Friday, 01'st May 2026
CytoDyn Inc. (CYDY) Discusses Corporate and Clinical Update With Focus on Leronlimab Development and Recent Financing Transcript
CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer
08:30am, Monday, 27'th Apr 2026
Program provides access to leronlimab for patients with limited treatment options while supporting ongoing clinical development
CytoDyn to Host Investor Webcast
08:30am, Thursday, 23'rd Apr 2026
VANCOUVER, Washington, April 23, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized m
CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026
08:30am, Wednesday, 22'nd Apr 2026
Ongoing Phase 2 study in metastatic colorectal cancer (mCRC) demonstrates early clinical and biomarker activity with leronlimab in combination with TAS-102 and bevacizumab, supporting CCR5 as a therap
CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study
04:10pm, Tuesday, 21'st Apr 2026
Enrollment concludes with just over 60 patients participating across seven clinical sites located throughout the United States
CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026
08:30am, Monday, 20'th Apr 2026
Translational study in metastatic triple-negative breast cancer (mTNBC) shows leronlimab-mediated CCR5 inhibition induces PD-L1 expression, modulates immune checkpoint signaling, and is associated wit
CytoDyn to Present at the AACR Annual Meeting 2026
08:30am, Tuesday, 14'th Apr 2026
VANCOUVER, Wash., April 14, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monocl
CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer
08:30am, Tuesday, 24'th Mar 2026
Preclinical data demonstrates leronlimab-mediated CCR5 inhibition enhances Temozolomide and radiation response in Glioblastoma
CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab
08:30am, Thursday, 05'th Mar 2026
VANCOUVER, Washington, March 05, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized mo
Leronlimab-mediated CCR5 blockade modulates T-Cell exhaustion pathways and PD-L1 Biology relevant to ICI response Durable Clinical Observations and Favorable Safety Profile Observed in Heavily Pretrea
Head-To-Head Review: BeOne Medicines (NASDAQ:ONC) versus CytoDyn (OTCMKTS:CYDY)
01:52am, Friday, 13'th Feb 2026
CytoDyn (OTCMKTS:CYDY - Get Free Report) and BeOne Medicines (NASDAQ: ONC - Get Free Report) are both medical companies, but which is the better investment? We will compare the two companies based on
Ironwood Pharmaceuticals (NASDAQ:IRWD) & CytoDyn (OTCMKTS:CYDY) Critical Survey
01:46am, Tuesday, 10'th Feb 2026
CytoDyn (OTCMKTS:CYDY - Get Free Report) and Ironwood Pharmaceuticals (NASDAQ: IRWD - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two busi
CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer
08:30am, Tuesday, 27'th Jan 2026
VANCOUVER, Washington, Jan. 27, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized mon
December 2025 Letter to Shareholders
08:30am, Tuesday, 16'th Dec 2025
VANCOUVER, Washington, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Dear Shareholders, As we close out the year and step with confidence and purpose into 2026, I want to extend my sincere appreciation for your s
